Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $215.00 short put and a strike $205.00 long put offers a potential 7.53% return on risk over the next 30 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $215.00 by expiration. The full premium credit of $0.70 would be kept by the premium seller. The risk of $9.30 would be incurred if the stock dropped below the $205.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.
The RSI indicator is at 68.23 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Thursday's Market Recap
Thu, 22 Jan 2015 23:26:22 GMT
Lieff Cabraser Announces Class Action Litigation Against Allergan Inc. – AGN
Thu, 22 Jan 2015 23:16:00 GMT
Business Wire – The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who sold the common stock of Allergan Inc. (“
Hungry Actavis pauses to digest Allergan
Wed, 21 Jan 2015 17:23:48 GMT
Financial Times – When David Pyott, chief executive of Allergan, hands out his business card, he describes it as “a collector's item that is about to go out of fashion”. After Actavis completes its $66bn takeover …
Valeant chief Pearson admits ‘miscalculation' in Allergan pursuit
Wed, 21 Jan 2015 17:09:58 GMT
Financial Times – Regrets? Valeant's chief executive, Mike Pearson, has a few. Eight weeks have passed since his pharmaceuticals group lost out in the race to buy Allergan, and Mr Pearson is remarkably candid about what …
Cramer's Stop Trading: ACT doesn't quit
Wed, 21 Jan 2015 14:55:00 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook